Alkane Energy is one of the UK’s fastest growing independent power generators.  The Company operates mid-sized 'gas to power' electricity plants providing both predictable and fast response capacity to the grid.  Alkane now has a total of 140MW of installed generating capacity and an electricity grid capacity of 160MW.

ANGLE plc is a specialist medtech company listed on the London Stock Exchange AIM market (AGL.L).

ANGLE's lead product is the Parsortix micro-fluidic cell separation device, which can capture very rare circulating tumour cells (CTCs) in cancer patient blood – even when there is less than one CTC in one billion healthy cells. In December 2013, ANGLE secured CE Mark regulatory authorisation for the clinical market in 2013 and FDA approval is planned for 2014.

The primary application is the capture of circulating tumour cells (CTCs) in patient blood for:

• Early detection of cancer;• Personalised cancer treatment;• Monitoring of cancer patients during treatment; and• Post-treatment monitoring of cancer patients in remission.

Valirx Plc is an oncology-focussed Biopharmaceutical Company, developing treatments and diagnostics. Technologies are selected by using rigorous clinical and commercial processes to address unmet market needs.

Clinical lead product is VAL201, a peptide for prostate cancer with follow-on indications in ovarian and breast cancers and endometriosis. Product VAL401, is a small molecule reformulation for lung cancers.

The Company’s proprietary technology platform, GeneICE, enables selective silencing of rebellious genes’ inappropriate activity. VAL101, the first GeneICE therapeutic, targets and reduces expression of Bcl-2, implicated in about half of cancers. GeneICE extension to neurology and inflammatory diseases will follow.

A novel diagnostic, the Nav3 system, detects pre-cancerous, cancerous and metastatic cells in tissue samples even before a tumour forms; indicating potential malignant formation.

Vipera is a leading provider of mobile financial services platforms. The Vipera platform provides the easiest, fastest, most cost-effective way to develop and operate mobile data services. Solutions powered by Vipera run today on more than 500,000 phones, on hundreds of mobile networks in many countries. Founded in 2005, Vipera has offices in Zurich, Milan and London.

ANGLE plc is a specialist medtech company listed on the London Stock Exchange AIM market (AGL.L).

ANGLE's lead product is the Parsortix micro-fluidic cell separation device, which can capture very rare circulating tumour cells (CTCs) in cancer patient blood – even when there is less than one CTC in one billion healthy cells. ANGLE secured CE Mark regulatory authorisation for the clinical market in December 2013 and FDA authorisation work is in progress.

The primary application is the capture of circulating tumour cells (CTCs) in patient blood for:

·         Early detection of cancer;

·         Personalised cancer treatment;

·         Monitoring of cancer patients during treatment; and

·         Post-treatment monitoring of cancer patients in remission.

Regenersis is a leading, strategic outsourcing partner to the world’s premier consumer technology brands. Regenersis has built an increasingly global network of repair centres, delivered double digit revenue and profit growth, through cross-sell related services to major OEMs and network operators. In addition, the Group has traction with its scalable, high margin Advanced Solutions offering across the mobile and set top box markets.

Valirx Plc is an oncology-focussed Biopharmaceutical Company, developing treatments and diagnostics. Technologies are selected by using rigorous clinical and commercial processes to address unmet market needs.

Clinical lead product is VAL201, a peptide for prostate cancer with follow-on indications in ovarian and breast cancers and endometriosis. Product VAL401, is a small molecule reformulation for lung cancers.

The Company’s proprietary technology platform, GeneICE, enables selective silencing of rebellious genes’ inappropriate activity. VAL101, the first GeneICE therapeutic, targets and reduces expression of Bcl-2, implicated in about half of cancers. GeneICE extension to neurology and inflammatory diseases will follow.

A novel diagnostic, the Nav3 system, detects pre-cancerous, cancerous and metastatic cells in tissue samples even before a tumour forms; indicating potential malignant formation.